Free Trial
→ A gold storm is coming – are you ready? (From Traders Agency) (Ad)tc pixel Free INKT Stock Alerts

MiNK Therapeutics (INKT) Competitors

MiNK Therapeutics logo
$12.76 +0.80 (+6.69%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$13.00 +0.25 (+1.92%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

INKT vs. FTFT, NKTX, MDWD, SLGL, and CRBP

Should you buy MiNK Therapeutics stock or one of its competitors? MarketBeat compares MiNK Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiNK Therapeutics include Future FinTech Group (FTFT), Nkarta (NKTX), MediWound (MDWD), Sol-Gel Technologies (SLGL), and Corbus Pharmaceuticals (CRBP).

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Comparatively, 1.5% of Future FinTech Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A
Future FinTech Group$3.83M1.70-$4.62M-$3.17N/A

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 174.29%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Future FinTech Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -37.76%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -118.57%
Future FinTech Group -37.76%-13.08%-10.33%

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, MiNK Therapeutics had 2 more articles in the media than Future FinTech Group. MarketBeat recorded 3 mentions for MiNK Therapeutics and 1 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 1.44 beat MiNK Therapeutics' score of 0.93 indicating that Future FinTech Group is being referred to more favorably in the news media.

Company Overall Sentiment
MiNK Therapeutics Positive
Future FinTech Group Positive

Summary

MiNK Therapeutics beats Future FinTech Group on 10 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Nkarta?

MiNK Therapeutics (NASDAQ:INKT) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, MiNK Therapeutics had 2 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for MiNK Therapeutics and 1 mentions for Nkarta. Nkarta's average media sentiment score of 1.89 beat MiNK Therapeutics' score of 0.93 indicating that Nkarta is being referred to more favorably in the news media.

Company Overall Sentiment
MiNK Therapeutics Positive
Nkarta Very Positive

MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat Nkarta's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -118.57%
Nkarta N/A -30.90%-24.20%

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 174.29%. Nkarta has a consensus price target of $10.75, indicating a potential upside of 295.22%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Nkarta
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A
NkartaN/AN/A-$104.08M-$1.34N/A

Summary

Nkarta beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to MediWound?

MiNK Therapeutics (NASDAQ:INKT) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, MediWound had 13 more articles in the media than MiNK Therapeutics. MarketBeat recorded 16 mentions for MediWound and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.93 beat MediWound's score of 0.44 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiNK Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MediWound
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, MediWound has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 174.29%. MediWound has a consensus target price of $34.00, indicating a potential upside of 147.42%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than MediWound.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
MediWound
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

MiNK Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MiNK Therapeutics' return on equity of 0.00% beat MediWound's return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -118.57%
MediWound -180.30%-67.22%-31.87%

MiNK Therapeutics has higher earnings, but lower revenue than MediWound. MediWound is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A
MediWound$16.96M10.41-$23.88M-$2.26N/A

Summary

MiNK Therapeutics beats MediWound on 10 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Sol-Gel Technologies presently has a consensus target price of $110.00, indicating a potential upside of 53.85%. MiNK Therapeutics has a consensus target price of $35.00, indicating a potential upside of 174.29%. Given MiNK Therapeutics' higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Sol-Gel Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sol-Gel Technologies
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40

In the previous week, Sol-Gel Technologies had 12 more articles in the media than MiNK Therapeutics. MarketBeat recorded 15 mentions for Sol-Gel Technologies and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.93 beat Sol-Gel Technologies' score of -0.26 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sol-Gel Technologies
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MiNK Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sol-Gel Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MiNK Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. MiNK Therapeutics' return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Sol-Gel Technologies-5.66% -3.17% -2.58%
MiNK Therapeutics N/A N/A -118.57%

Sol-Gel Technologies has higher revenue and earnings than MiNK Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sol-Gel Technologies$19.39M10.36-$6.13M-$0.34N/A
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A

Summary

Sol-Gel Technologies beats MiNK Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Corbus Pharmaceuticals?

MiNK Therapeutics (NASDAQ:INKT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

MiNK Therapeutics' return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -118.57%
Corbus Pharmaceuticals N/A -70.89%-61.78%

MiNK Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 174.29%. Corbus Pharmaceuticals has a consensus target price of $42.00, suggesting a potential upside of 469.11%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Corbus Pharmaceuticals
2 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.75

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A
Corbus PharmaceuticalsN/AN/A-$78.54M-$5.82N/A

MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, meaning that its stock price is 157% more volatile than the broader market.

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than MiNK Therapeutics. MarketBeat recorded 7 mentions for Corbus Pharmaceuticals and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.93 beat Corbus Pharmaceuticals' score of 0.03 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiNK Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corbus Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Corbus Pharmaceuticals beats MiNK Therapeutics on 8 of the 13 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INKT vs. The Competition

Export
MetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$59.58M$3.24B$6.47B$12.54B
Dividend YieldN/A2.38%2.69%5.22%
P/E Ratio-4.4917.7822.1724.18
Price / SalesN/A315.63525.02112.26
Price / CashN/A111.6441.3457.13
Price / Book-4.216.639.866.72
Net Income-$12.49M$24.20M$3.57B$337.19M
7 Day Performance4.59%-4.39%-2.45%-0.74%
1 Month PerformanceN/AN/AN/A-1.69%
1 Year Performance79.72%45.50%26.50%33.10%

MiNK Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INKT
MiNK Therapeutics
2.5236 of 5 stars		$12.76
+6.7%		$35.00
+174.3%		+79.0%$59.58MN/AN/A30
FTFT
Future FinTech Group
0.9765 of 5 stars		$1.17
-0.8%		N/A-79.3%$6.93M$3.83MN/A70
NKTX
Nkarta
3.6871 of 5 stars		$3.03
flat		$10.75
+254.8%		+53.7%$216.78MN/AN/A140
MDWD
MediWound
3.3912 of 5 stars		$16.58
-1.5%		$35.00
+111.1%		-36.4%$216.43M$16.96MN/A80
SLGL
Sol-Gel Technologies
3.641 of 5 stars		$76.73
+12.3%		$110.00
+43.4%		+872.7%$215.60M$19.39MN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners
A gold storm is coming – are you ready?
The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...
Traders Agency | Sponsoredtc pixel
The SpaceX S-1 changes everything
SpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...
Crypto 101 Media | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel